Report: Injectable antibodies top growth chart

10/11/2007 | NYTimes.com

Sales of injectable monoclonal antibodies will grow 14% annually from 2006 to 2012, preserving their status as the fastest-growing class of drugs during the next five years, market analyst Datamonitor says in its latest report. Antibody-based drugs already are popular for the treatment of cancer and rheumatoid arthritis and currently generate $20 billion in global revenue.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC